Stock Taper
SCREENER COMPARE ANY 2 STOCKS
PRLD
PRELUDE THERAPEUTICS INCORPORATED
NASDAQ
$5.46
▲ UP 4.00% (0.21)

KEY STATISTICS

Market Cap$311.42 M
52w High$6.83
52w Low$0.98
Dividend Yield—
Frequency—
P/E-5.46
Volume400.28K
Shares Out.78.50M

COMPANY

LEADERSHIP

Krishna Vaddi
CHIEF EXECUTIVE
Krishna Vaddi

COMPENSATION 2026

Salary$615,441
Stock Awards$0
Incentive Plan Pay$309,465
All Other Comp.$10,350
Total$1,348,000

ABOUT

SECTOR
Healthcare
WENT PUBLIC
September 25, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
79

PRICE TARGET

Target High$8.00
Target Low$8.00
Target Median$8.00
Target Consensus$8.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$35.33M
NOV
11
WED

PRICE

$5.46 ▲ UP 4.00% (+$0.21)
$5.20$5.30$5.40$5.509:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM5.46

About Prelude Therapeutics Incorporated

https://www.preludetx.com ↗

Prelude Therapeutics, a clinical-stage oncology company, develops novel precision cancer medicines like PRT543, PRT811, and PRT1419, targeting underserved patients across various solid tumors and hematologic malignancies.

INDUSTRY

Biotechnology

A PRODUCT PRELUDE THERAPEUTICS INCORPORATED IS KNOWN FOR

PRT12396
PRT12396

PRT12396, a mutant-selective JAK2V617F inhibitor, received FDA IND clearance in February 2026 to begin clinical trials targeting myeloproliferative neoplasms, offering a novel, highly selective cancer treatment approach.

COMPETITORS

COMPETITOR
BMY COMPARE
GERN COMPARE
INCY COMPARE
SNDX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
50
LISTED HERE
10
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.5M
XSU.TO
0.00% · 647.8K
XRS2.DE
0.00% · 25.2K
OMFS
0.04% · 19.7K
R2SC.L
0.00% · 13.3K
RSSL
0.01% · 13.2K
AVSC
0.00% · 9.9K
DFMC
0.00% · 8.7K
URTY
0.00% · 1.1K
FSEG
0.07% · 879

INSTITUTIONAL OWNERSHIP

SHARES OWNED
40.53%
HOLDERS
71
TOP 12 OF 71 · RANKED BY POSITION SIZE
Orbimed Advisors LLC
10.9M sh · $37.31M
Baker Bros. Advisors LP
10.1M sh · $29.36M
Boxer Capital, LLC
1.7M sh · $3.54M
Kynam Capital Management, LP
1.6M sh · $5.45M
Vanguard Group Inc
1.4M sh · $4.1M
Millennium Management LLC
1.1M sh · $1.65M
Blackrock Inc.
1.1M sh · $4.07M
Ecor1 Capital, LLC
947.0K sh · $3.24M
Two Sigma Investments, LP
923.6K sh · $3.16M
Price T Rowe Associates Inc /Md/
876.3K sh · $1.26M
Sphera Funds Management Ltd.
558.3K sh · $1.91M
Renaissance Technologies LLC
544.0K sh · $783.36K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER:
BAKER BROS. ADVISORS LP
Purchase · 38.0K shares
2026-06-09
★
DIRECTOR
Dorton Katina
Purchase · 38.0K shares
2026-06-09
★
DIRECTOR
Babler Martin
Purchase · 38.0K shares
2026-06-09
★
DIRECTOR, 10 PERCENT OWNER:
Bonita David P
Purchase · 38.0K shares
2026-06-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
MARKET OUTPERFORM 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Citizens MARKET OUTPERFORM

SECTORS PEERS

PEERPRICE
AVTX$19.27COMPARE
ENTA$14.15COMPARE
OBIO$4.92COMPARE
FHTX$4.92COMPARE
EPRX$7.66COMPARE
PYXS$3.96COMPARE
IVA$4.76COMPARE
IMRX$4.91COMPARE